ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1029 • 2016 ACR/ARHP Annual Meeting

    Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of Th17-Cell Mediated Autoimmune Arthritis

    Mattias N. D. Svensson1,2, Karen M. Doody1, Cristiano Sacchetti1,2, Dennis J. Wu1, Gisen Kim3, Annelie Hellvard4, Brith Bergum4, Piotr Mydel4, Mitchell Kronenberg3, Michel L. Tremblay5 and Nunzio Bottini1,2, 1Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2Department of Medicine, University of California, San Diego, La Jolla, CA, 3Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 4Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, 5Goodman Cancer Centre, McGill University, Montréal, QC, Canada

    Background/Purpose: Genome-wide association studies have linked polymorphisms in the PTPN2 locus to rheumatoid arthritis (RA). PTPN2 encodes the tyrosine phosphatase TC-PTP, an important regulator of…
  • Abstract Number: 1030 • 2016 ACR/ARHP Annual Meeting

    Synovial Tissue Resident Macrophages Play the Protective Role in the Development of Inflammatory Arthritis in CD11c-Flip-KO Mice

    Qi Quan Huang1, Renee E. Doyle2, Robert Birkett3 and Richard M. Pope2, 1Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Medicine/Rheumatology, Northwestern University, Chicago, IL

    Synovial Tissue Resident Macrophages Play the protective role in the Development of Inflammatory Arthritis in CD11c-Flip-KO MiceQi-Quan Huang1, Renee Doyle1, Robert Birkett1 and Richard M.…
  • Abstract Number: 1031 • 2016 ACR/ARHP Annual Meeting

    Glucocorticoid Receptor Dimerization in Stromal Cells Modulates Macrophage Polarization during Serum Transfer-Induced Arthritis

    Mascha Koenen1, Ulrike Baschant2,3, Stephan Culemann3,4, Tobias Kockmann5, Hans-Michael Kaltenbach6, Sabine Vettorazzi1,3, Paolo Nanni7, Bernd Roschitzki8, Ulrich Auf dem Keller9 and Jan P. Tuckermann1,3, 1Institute for Comparative Molecular Endocrinology, University of Ulm, Ulm, Germany, 2Dep. of Medicine III, TU Dresden, Dresden, Germany, 3Leibniz Institute on Aging, FLI Jena, Jena, Germany, 4Dep. of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, 5Institute for Molecular Health Sciences, ETH Zürich, Zürich, Switzerland, 6Dep. of Biosystems Science and Engineering, ETH Zürich, Zürich, Germany, 7Functional Genomics Center Zurich, University and ETH Zurich, Zürich, Switzerland, 8Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, 9Institute for Molecular Health Sciences, ETH Zürich, Zürich, Germany

    Background/Purpose: Rheumatoid arthritis is commonly treated with potent anti-inflammatory glucocorticoids (GC), despite severe side effects such as osteoporosis and insulin resistance associated with chronic dosing…
  • Abstract Number: 1032 • 2016 ACR/ARHP Annual Meeting

    Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis

    Katarzyna Matyja1,2, Matthieu Ribon1,2, Roxane Hervé1,2, Delphine Lemeiter1,2, Ken Tsumiyama3, Natacha Bessis1,2, Shunichi Shiozawa3, Marie-Christophe Boissier1,2,4 and Patrice Decker1,2, 1Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, 2UMR 1125, Inserm, Bobigny, France, 3Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, 4Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France

    Background/Purpose:  Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
  • Abstract Number: 1033 • 2016 ACR/ARHP Annual Meeting

    Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis

    Wen Sun1,2, Hengwei Zhang3, Hua Wang1,2, Yahui Grace Chiu4, Christopher T. Ritchlin5, Amy Kiernan1, Brendan Boyce1 and Lianping Xing1, 1University of Rochester Medical Center, Rochester, NY, 2Nanjing Medical University, Nanjing, China, 3Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 4Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose:  Increased expression of Notch signaling molecules has been reported in synovial samples of patients with rheumatoid arthritis (RA). However, the identity of the cell…
  • Abstract Number: 1034 • 2016 ACR/ARHP Annual Meeting

    Microrna-146a Controls Local Bone Destruction By Regulating Fibroblast Induced Osteoclastogenesis in Inflammatory Arthritis

    Victoria Saferding1, Antonia Puchner2, Eliana Goncalves-Alves3, Melanie Hofmann3, Julia Brunner4, Emine Sahin4, Silvia Hayer5, Philippe Georgel6, Marije M. Koenders7, Gernot Schabbauer4, Josef S. Smolen8, Günter Steiner9, Kurt Redlich3 and Stephan Blüml10, 1Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Vascular Biology and Thrombosis research, Medical University of Vienna, Vienna, Austria, 5Waehringer Guertel 18-20 A-A09, Medical University of Vienna, Vienna, Austria, 6Centre de Recherche en Immunologie et Hématologie, Université de Strasbourg, Strasbourg, France, 7Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 8Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 9Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 10Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: MicroRNA (MiR-) 146a plays an important role in the regulation of the innate immune response and has also been shown to suppress cancer development…
  • Abstract Number: 1035 • 2016 ACR/ARHP Annual Meeting

    The Prognostic Value of Different Auto-Antibodies for Arthritis Development in Patients with Clinically Suspect Arthralgia

    Robin M ten Brinck1, Hanna W van Steenbergen1, Marije K. Verheul1, Leendert A. Trouw2 and Annette HM van der Helm-van Mil3, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Previous longitudinal studies in arthralgia patients studied Rheumatoid Factor (IgM-RF) and Anti-Citrullinated Protein Antibodies (ACPA) in relation to arthritis development. Participants in these studies…
  • Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting

    Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis

    Paul-Peter Tak1,2,3, Marieke E. Doorenspleet4, Maria de Hair5, Paul L. Klarenbeek6, Marian van Beers-Tas7, Antoine H.C. van Kampen8, Dirkjan van Schaardenburg9,10, Danielle M. Gerlag11,12, Frank Baas13 and Niek de Vries14, 1Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Currently: GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 3currently: Ghent University, Ghent, Belgium & Cambridge University, Cambridge, United Kingdom, 4Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 6Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 7Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, 8Dept Clin Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, 9Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 10Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, 11Clinical Immunology & Rheumatology, ARC | Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 12Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, 13Department of Genome Analysis, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, 14Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…
  • Abstract Number: 1037 • 2016 ACR/ARHP Annual Meeting

    Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort

    Monika Hansson1, Linda Mathsson-Alm2, Anthony Marotta3 and Sascha Swiniarski4, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Thermo Fisher Scientific, Uppsala, Sweden, 3Augurex Life Sciences Corp., Vancouver, BC, Canada, 4ImmunoDiagnostics Division Thermo Fisher Scientific, Phadia GmbH, Freiburg, Germany

    Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) coupled with an effective treatment strategy is a key imperative in the effective management of disease. Anti-citrullinated peptide…
  • Abstract Number: 1038 • 2016 ACR/ARHP Annual Meeting

    Functional Disability in Patients Presenting with Clinically Suspect Arthralgia and Progression to Clinical Arthritis

    Robin M ten Brinck1, Hanna W van Steenbergen1, Lukas Mangnus2, Leonie E Burgers1, Monique Reijnierse3, Tom WJ Huizinga1 and Annette HM van der Helm-van Mil4, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: A phase of arthralgia precedes the emergence of rheumatoid arthritis (RA). It is unknown if patients have functional limitations in this phase. We assessed…
  • Abstract Number: 1039 • 2016 ACR/ARHP Annual Meeting

    Estimation of the Risk of Developing Rheumatoid Arthritis in High-Risk Subjects : Systematic Review and Meta-Analysis

    François Vercruysse1, Vincent Germain1, Thomas Barnetche2, Marie-Elise Truchetet3 and Thierry Schaeverbeke2, 1Rheumatology, CHU Pellegrin, Bordeaux, France, BORDEAUX, France, 2Rheumatology, CHU Pellegrin, Bordeaux, France, Bordeaux, France, 3CHU Pellegrin, Bordeaux, France, Bordeaux, France

    Background/Purpose: Identifying individuals at risk for rheumatoid arthritis (RA) development is a prerequisite to understand preclinical events and to develop prevention. Based on a systematic…
  • Abstract Number: 1040 • 2016 ACR/ARHP Annual Meeting

    Stressful Life Events : A Trigger for Rheumatoid Arthritis Onset within a Year. a Case-Control Study

    Jimmy Gross1, Nadia Oubaya2,3, Florent Eymard1, Alexia Hourdille1, Xavier Chevalier1 and Sandra Guignard1, 1Department of Rheumatology, APHP Henri Mondor hospital, Créteil, France, 2Public Health Department, F-94000, APHP Henri Mondor hospital, Créteil, France, 3DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), F-94000, Université Paris-Est, UPEC,, Créteil, France

    Background/Purpose: To assess the association between recent stressful life events and rheumatoid arthritis (RA) onset. Methods: We conducted a monocentric case-control study of in and…
  • Abstract Number: 1041 • 2016 ACR/ARHP Annual Meeting

    Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study

    P Mease1, AB Gottlieb2, D van der Heijde3, Oliver FitzGerald4, A Johnsen5, M Nys6, S Banerjee5 and D Gladman7, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, 3Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, 5Bristol-Myers Squibb, Princeton, NJ, 6Bristol-Myers Squibb, Braine-l’Alleud, Belgium, 7Rheumatology, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, showed promise for the treatment of PsA in a Phase II trial.1 This prompted the conduct of…
  • Abstract Number: 1042 • 2016 ACR/ARHP Annual Meeting

    Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Desiree van der Heijde1, Xenofon Baraliakos2, Kay-Geert Hermann3, Robert Landewé4, Pedro Machado5, Walter Maksymowych6, Owen Davies7, Natasha de Peyrecave7, Bengt Hoepken8, Lars Bauer8, Tommi Nurminen8 and Jürgen Braun9, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 3Charité – University Medicine Berlin, Berlin, Germany, 4Rheumatology, Academic Medical Center, Amsterdam & Zuyderland Medical Center Heerlen, Amsterdam, Netherlands, 5Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, 6Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Monheim, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: RAPID-axSpA (NCT01087762) was a long-term study in patients (pts) with axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP). This is the first report of…
  • Abstract Number: 1043 • 2016 ACR/ARHP Annual Meeting

    Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28

    Atul A. Deodhar1, John D. Reveille2, Diane D. Harrison3, Lilianne Kim4, Kim Hung Lo4 and Elizabeth C. Hsia5,6, 1Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 2Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 3Janssen Research & Development, LLC., Horsham, PA, 4Janssen Research & Development, LLC., Spring House, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the…
  • « Previous Page
  • 1
  • …
  • 1666
  • 1667
  • 1668
  • 1669
  • 1670
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology